|Bid||0.00 x 1000|
|Ask||0.00 x 800|
|Day's range||59.28 - 60.05|
|52-week range||57.04 - 85.97|
|Beta (5Y monthly)||0.55|
|PE ratio (TTM)||59.61|
|Earnings date||02 Feb 2021 - 08 Feb 2021|
|Forward dividend & yield||2.72 (4.53%)|
|Ex-dividend date||14 Dec 2020|
|1y target est||73.72|
When you think about dividend stocks, biotechs probably don't immediately come to mind. Gilead Sciences' (NASDAQ: GILD) dividend program especially stands out. The company arguably offers the best dividend of any biotech.
Gilead Sciences (NASDAQ: GILD) started the year strong. As a result, while the rest of the stock market slid, Gilead did just the opposite. To make matters worse, the World Health Organization (WHO) recently advised against using remdesivir as a treatment for COVID-19.
Daniel O'Day has made increasingly larger deals in an effort to improve the company's portfolio of cancer drugs.